Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by StockNews.com

StockNews.com downgraded shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note issued to investors on Monday.

Other research analysts also recently issued research reports about the stock. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Tuesday, January 7th. HC Wainwright started coverage on Immunic in a report on Monday, November 25th. They set a “buy” rating and a $10.00 price target for the company. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Stock Down 0.1 %

Shares of IMUX stock opened at $0.96 on Monday. The company has a market cap of $86.49 million, a price-to-earnings ratio of -0.78 and a beta of 1.87. The firm has a 50 day moving average of $1.07 and a 200-day moving average of $1.28. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11.

Institutional Trading of Immunic

Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Immunic in the third quarter valued at $50,000. Jane Street Group LLC boosted its position in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. HB Wealth Management LLC purchased a new position in shares of Immunic in the fourth quarter worth about $81,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. Finally, State Street Corp lifted its stake in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.